Sinotherapeutics was founded in August 2012. It is a specialty pharma focus on the R&D, registration, manufacture and commercialization of complex generic products as well as innovative formulation products (505B2). The company aims to achieve commercialize its product globally, and to provide cost-effective high-quality products to international markets. The company has launched its product in multiple markets around the world, including metabolic, oncoly and CNS products.
The company has its headquarter and R&D center located in the high-tech park in Pudong Zhangjiang district, Shanghai, China. The R&D center is well setup for formulation preparations, GMP analytical labs, and GMP pilot plants.The company also has a wholly owned commercial oral solid dosage form manufacture facilities, and high-potency formulation suits, both are located in Haimen City Jiangsu Provice, and have been audited and qualified multipletimes by US FDA and Chinese NMPA.
The company's business also involves a small scale of the R&D, production and sales of high-end nutraceutical, nutritional products and dietary supplements.
Sinotherapeutics has a manufacturing facilities for multiple oral dosage forms with a size of about 55 thousand square meters.
The manufacture facility has been successfully passed multiple times the audits by FDA and NMPA.
Management Team has many years of industrial experience in product lifecycle management and project management.
Better Medicines Better Lives
Honesty and Dedication, Shared Efforts for Shared Future
Be Great In Contemplation, Articulation Execution and Realization
To improve patient’s health and quality of life with pharmaceutical products that are of high quality and cost-effective, through technological optimization and innovation.
To be a leader in the specialty pharmaceutical industry in China and the rest of the world, serving the public and society with pharmaceutical products that are of high quality and cost-effectiveness.
01Posaconazole Delayed-Released Tablets was approved by Chinese NMPA and launched in the Chinese market, and by Australia and launched in the Australia market.
02Take an equity stake in Chengdu D-innovation Pharmaceutical Co., Ltd, a high-tech company integrating R&D, manufacturing and sale of pharmaceutical intermediates and APIs.
01Company competed formalization of SinoT equity share holding and assignments, which enable SinoT to become an equity company with multiple registered shareholders.
01Propafenone Extended Release Tablets was approved by FDA and launched in US market.
02Posaconazole Delayed-Released Tablets was approved by FDA and launched in the US market as the first generic.
03Haimen Manufacturing facility received and passed on-site audit by FDA for the third time.
04Company successfully applied for and received the Shanghai Enterprise Patent Pilot Unit---a recognition of company’s heavy engagement in patent applications.
01Company completed series-A fund rasing of ￥200 million RMB.
02Quetiapine Fumarate Extended Release Tablets was approved by FDA and launched in US marketed.
03Haimen Manufacturing facility received and passed the on-site audit by FDA for the second time.
01Sinotherapeutics Inc. was recognized as one of the high-tech enterprises in China;
02Bupropion Extended-Release Tablets was approved by FDA and launched in the US marketed;
03Metformin Hydrochloride Extended-Release Tablets was approved by FDA and launched in US marketed.
01Shanghai R&D center and Haimen manufacturing facility received and passed the on-site audits conducted by FDA for the first time.
01Haimen Pharma Inc Manufacturing facility received a certification of GMP issued by NMPA.
01Acquired Haimen Pharma Inc. as the wholly owned manufacturing facility of oral solid dosage forms.
02Sinonutraceutical co.,Ltd. founded, dedicated to the R&D, manufacturing and distribution of high-end nutraceutical/nutritional and dietary supplement products.